Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.

Axelsson S, Hjorth M, Ludvigsson J, Casas R.

Diabet Med. 2012 Oct;29(10):1272-8. doi: 10.1111/j.1464-5491.2012.03710.x.

PMID:
22587593
2.

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E, Mallone R, Ludvigsson J, Casas R.

PLoS One. 2011;6(12):e29008. doi: 10.1371/journal.pone.0029008.

3.

Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.

Hedman M, Faresjö M, Axelsson S, Ludvigsson J, Casas R.

Clin Exp Immunol. 2008 Sep;153(3):360-8. doi: 10.1111/j.1365-2249.2008.03720.x.

4.
5.

Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.

Pihl M, Akerman L, Axelsson S, Chéramy M, Hjorth M, Mallone R, Ludvigsson J, Casas R.

Clin Exp Immunol. 2013 Jun;172(3):394-402. doi: 10.1111/cei.12078.

6.

C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential.

Andrew DP, Ruffing N, Kim CH, Miao W, Heath H, Li Y, Murphy K, Campbell JJ, Butcher EC, Wu L.

J Immunol. 2001 Jan 1;166(1):103-11.

7.

GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R.

Clin Immunol. 2011 Jan;138(1):117-26. doi: 10.1016/j.clim.2010.10.004.

PMID:
21044870
8.

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R.

N Engl J Med. 2008 Oct 30;359(18):1909-20. doi: 10.1056/NEJMoa0804328.

9.

Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).

Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R.

Diabetes Metab Res Rev. 2010 Oct;26(7):559-68. doi: 10.1002/dmrr.1126.

PMID:
20830731
10.

Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes.

Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann I, Schroeder S, Paschke R, Kiess W.

Diabetes. 2002 Aug;51(8):2474-80.

11.

Selective recruitment of CXCR3+ and CCR5+ CCR4+ T cells into synovial tissue in patients with rheumatoid arthritis.

Norii M, Yamamura M, Iwahashi M, Ueno A, Yamana J, Makino H.

Acta Med Okayama. 2006 Jun;60(3):149-57.

12.

Selective lymphocyte chemokine receptor expression in the rheumatoid joint.

Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, Ponath P, Pope RM, Koch AE.

Arthritis Rheum. 2001 Dec;44(12):2750-60.

PMID:
11762935
13.

IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.

J Leukoc Biol. 2002 Oct;72(4):735-42.

PMID:
12377943
14.

GAD-alum immunotherapy in Type 1 diabetes mellitus.

Morales AE, Thrailkill KM.

Immunotherapy. 2011 Mar;3(3):323-32. doi: 10.2217/imt.11.9. Review.

PMID:
21395375
15.

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group..

Lancet. 2011 Jul 23;378(9788):319-27. doi: 10.1016/S0140-6736(11)60895-7.

16.

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Åman J, Kärdell G, Neiderud Helsingborg J, Lundström G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanås R, Larsson K, Rathsman B, Forsgren H, Desaix H, Forsander G, Nilsson NÖ, Åkesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A, Rica I, Barrio R, Clemente M, López Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S.

N Engl J Med. 2012 Feb 2;366(5):433-42. doi: 10.1056/NEJMoa1107096.

17.

Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children.

Jonson CO, Pihl M, Nyholm C, Cilio CM, Ludvigsson J, Faresjö M.

Clin Exp Immunol. 2008 Aug;153(2):174-81. doi: 10.1111/j.1365-2249.2008.03625.x.

18.

CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease.

Jo Y, Matsumoto T, Yada S, Fujisawa K, Esaki M, Onai N, Matsushima K, Iida M.

Clin Exp Immunol. 2003 May;132(2):332-8.

19.

GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.

Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Akerman L, Casas R; Clinical GAD-Study Group in Sweden..

Diabetes Metab Res Rev. 2014 Jul;30(5):405-14. doi: 10.1002/dmrr.2503.

PMID:
24302596
20.

CD8+ T lymphocytes specific for glutamic acid decarboxylase 90-98 epitope mediate diabetes in NOD SCID mouse.

Sévère S, Gauvrit A, Vu AT, Bach JM.

Mol Immunol. 2007 Apr;44(11):2950-60.

PMID:
17336387
Items per page

Supplemental Content

Support Center